Alpha Articles
Amarillo gets orphan drug status for Veldona
23 August 2000
FDA accepts Aronex' Atragen NDA amendment
23 August 2000
Biogen, Elan link up on Antegren antibody
18 August 2000
Maxim and Roche link up in cancer and hep C
10 August 2000
Stock Commentary Tokyo
10 August 2000
Cambridge Antibody: R&D update
2 August 2000
Pharming's first half revenues leap 75%
2 August 2000
Evotec bids $475 mill for Oxford Asymmetry
31 July 2000
Japan ups warning on Shionogi's Flomox
28 July 2000
Transkaryotic files BLA for Replagel
20 June 2000
Progenics' cancer vaccine loses support
30 May 2000
Research partners boosting Pharming
12 May 2000
Genzyme acquires Pompe disease therapy
26 April 2000
SciClone gains Orphan Drug Status for Zadaxin
29 March 2000
Pharming reports 1999 revenues up 54%
29 March 2000
Ensuring cannabinoids' potential does not go to pot
24 March 2000
Stock Commentary Tokyo
23 March 2000
Pfizer's Cardura "no better" than diuretic
16 March 2000
Stock Commentary Tokyo
9 March 2000
Merck ends BPH deal with Synaptic
8 March 2000
Yoshitomi US ops okay
7 March 2000
Product pipeline pushes Pharming shares
6 March 2000
Fujisawa and Elder sign marketing pact
2 March 2000
PPL reports progress with AAT therapy
17 February 2000
TKT gets $2.5m milestone, to present alpha-gal data this year
13 January 2000
Novartis' STI-570 promising in CML
8 December 1999
Stock Commentary Tokyo
2 December 1999
Stock Commentary New York
25 November 1999
BioMarin and Genzyme to conduct additional Ph III Aldurazyme trial
24 November 1999
Celltech Chiroscience to file for CDP571 approval in 2000
23 November 1999
DeveloGen AG: using developmental biology in regenerative medicine
11 November 1999
Pharming completes Ph II study in Pompe's disease
4 November 1999
Stock Commentary Tokyo
28 October 1999
Stock Commentary Tokyo
21 October 1999
New generation of anti-HIV drugs unveiled at ICAAC
13 October 1999
Stock Commentary Tokyo
11 October 1999
India's Alpha seeks govt rescue deal
11 October 1999
Stock Commentary Tokyo
30 September 1999
BioMarin/Genzyme report positive enzyme replacement therapy data
22 September 1999
Mixed fortunes for companies from latest ODAC deliberations
21 September 1999
Merck & Co pulls out of BPH collaboration with Synaptic
16 September 1999
Dynavax looks to IPO in 2000 to progress DNA immunization
16 September 1999
European launches for BI's TNF cancer drug - corrected story
16 September 1999
European launches for BI's TNF cancer drug
15 September 1999
Stock Commentary Tokyo
2 September 1999
Glaxo sells plant to AHP for $60 million
26 August 1999
Roferon-A as adjuvant therapy for melanoma
10 August 1999
Stock Commentary Tokyo
15 July 1999
Maxim on track for first product in 2001
7 July 1999
Stock Commentary Tokyo
1 July 1999
Knoll and Eisai to codevelop D2E7 in Japan
24 June 1999
Positive data with CAT, BASF arthritis drug
15 June 1999
Data on CAT's arthritis drug expected this month
4 June 1999
SunPharm/W-L drug shrinks renal tumors
26 May 1999
Phase II data on TAb's sepsis drug positive
20 May 1999
Rebetron gets first-line approval in Canada
5 May 1999
Phase III interferon trial expanded at Amarillo
29 April 1999
Sigma-Tau licenses hepatitis drug Zadaxin
28 April 1999
Stock Commentary Tokyo
14 April 1999
Isis, Elan link up for oral antisense drugs
13 April 1999
Clonidine poisoning in ADHD children
12 April 1999
Pharming gets 110 mill franc boost in Belgium
12 March 1999
Stock Commentary New York
11 March 1999
Pharming posts strong full-year revenue growth
1 March 1999
PPL positive on results of AAT trial
24 February 1999
Collaborations progress at Sweden's Karo Bio
19 February 1999
New guidelines on hypertension from ISH
15 February 1999
Bioject - one step ahead in a needle-free world
10 February 1999
Yoshitomi injects more capital in US subsidiary
5 February 1999
SciClone's Zadaxin approved for hepatitis B and C in Venezuela
26 January 1999
Novartis' iloperidone in Phase III in USA
21 January 1999
Aronex tests Atragen in renal cancer
21 January 1999
Abbott seeks approval for new sedative
12 January 1999
Vion develop antitumor vector from bacteria
30 December 1998
TKT Starts Alpha-Gal A Trial In Fabry's
16 December 1998
Pharming Seeks Listing On AEX
15 December 1998
ETEX Corp Receive EU Approval For Biobon Bone Substitute
30 November 1998
Amarillo Biosciences Starts Enrollment in Phase III For Dry Mouth
30 November 1998
D2E7 Reduces Disease Activity in Rheumatoid Arthritis Patients
19 November 1998
Yoshitomi Recalls Plasma Products In USA
6 November 1998
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
